Ligand ID: 8N6 Drugbank ID: DB01132(Pioglitazone) Indication:Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label]. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 2amq | 3C-LIKEPROTEINASE (SARSr-CoV;syntheticconstruct) | 5 / 12 | CYH B 85HIS B 163LEU D 4PHE B 181TYR B 161 | 1.74A | 22.39 | NonePJE D 5 (-3.7A)PJE D 5 ( 4.1A)NoneNone | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 2dd8 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | PHE S 364LEU S 412LEU S 355LEU S 374TYR S 352 | 1.75A | 20.00 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 2fe8 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | PHE C 148CYH C 149TYR C 84LEU C 88LEU C 133 | 1.68A | 20.30 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 2ghv | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | PHE E 364TYR E 352LEU E 355LEU E 377LEU E 499 | 1.55A | 20.21 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 2ozk | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARSr-CoV) | 5 / 12 | CYH B 290LEU B 245HIS B 249LEU B 254LEU B 265 | 1.75A | 21.43 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 2q6g | POLYPEPTIDE CHAINREPLICASEPOLYPROTEIN 1AB (SARS-COVBJ01) | 5 / 12 | CYH A 85HIS A 163LEU C 5PHE A 181TYR A 161 | 1.73A | 21.99 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 3i6g | HLA, A-2MEMBRANE PROTEIN (Homosapiens) | 5 / 12 | SER C 5HIS A 114TYR A 99LEU C 1TYR A 116 | 1.63A | 15.09 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 3i6l | BETA-2-MICROGLOBULINHLA, A-24 (Homosapiens) | 5 / 12 | PHE E 56SER D 11HIS D 70LEU D 95TYR D 116 | 1.77A | 17.08 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 3iwm | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | PHE C 66CYH C 22HIS C 41LEU C 87LEU C 27 | 1.67A | 21.99 | NoneNonePJE G 5 (-4.9A)NonePJE G 5 (-4.2A) | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 3m3t | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH A 117SER A 144HIS A 163MET A 17LEU A 141 | 1.80A | 21.99 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 3scl | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | CYH A 498SER A 502MET A 474LEU A 456LEU A 503 | 1.78A | 19.50 | None CL A 902 ( 4.8A)NoneNoneNone | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 4ovz | PAPAIN-LIKEPROTEINASE (SARS-COVUrbani) | 5 / 12 | PHE B 148CYH B 149TYR B 84LEU B 88LEU B 133 | 1.68A | 21.83 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 4tww | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH B 300SER B 301LEU B 253PHE B 3LEU A 141 | 1.79A | 21.02 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 5c8t | GUANINE-N7METHYLTRANSFERASE (SARSr) | 5 / 12 | SER D 194LEU D 192PHE D 183MET D 241LEU D 109 | 1.41A | 20.35 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 5tl6 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | PHE B 148CYH B 149TYR B 84LEU B 88LEU B 133 | 1.69A | 22.12 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 5x5b | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 12 | PHE A 364LEU A 412LEU A 355LEU A 374TYR A 352 | 1.62A | 12.91 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 5y3e | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 5 / 12 | PHE A 148CYH A 149TYR A 84LEU A 88LEU A 133 | 1.72A | 20.93 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6acj | ACE2 (Homosapiens) | 5 / 12 | SER D 420PHE D 314HIS D 373LEU D 370LEU D 418 | 1.78A | 19.50 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6iex | MHC CLASS I ANTIGEN (Homosapiens;SARSr-CoV) | 5 / 12 | PHE A 22SER A 77LEU C 7LEU A 95TYR A 116 | 1.74A | 21.79 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m1d | ACE2SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 5 / 12 | PHE B 746SER A 206PHE A 141MET A 137LEU A 199 | 1.70A | 17.00 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | SER A 267PHE A 230LEU A 250LEU A 208TYR A 209 | 1.74A | 22.62 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | SER B 267PHE B 230LEU B 250LEU B 208TYR B 209 | 1.73A | 22.62 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 635LEU A 663MET A 626LEU A 469LEU A 636 | 1.70A | 16.10 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6nus | NSP12 (SARSr-CoV) | 5 / 12 | SER A 635LEU A 663MET A 626LEU A 469LEU A 636 | 1.79A | 16.28 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.59A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | CYH B 143SER B 139LEU B 153PHE B 116LEU B 109 | 1.41A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | CYH A 143SER A 139LEU A 153PHE A 116LEU A 109 | 1.47A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE A 802LEU A1049PHE A 898MET A 902LEU A 878 | 1.73A | 13.49 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | SER A 221PHE A 58LEU A 56LEU A 223TYR A 91 | 1.56A | 13.49 | None | ||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | PHE B 116CYH B 143SER B 139LEU B 164LEU B 109 | 1.57A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.58A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE B 147CYH B 148TYR B 83LEU B 87LEU B 132 | 1.67A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.63A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.57A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | PHE A 320CYH A 347SER A 343LEU A 368LEU A 313 | 1.59A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE B 116CYH B 143SER B 139LEU B 164LEU B 109 | 1.60A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE D 116CYH D 143SER D 139LEU D 164LEU D 109 | 1.64A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE C 116CYH C 143SER C 139LEU C 164LEU C 109 | 1.60A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.60A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 5 / 12 | PHE A 147CYH A 148TYR A 83LEU A 87LEU A 132 | 1.67A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.59A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE B 116CYH B 143SER B 139LEU B 164LEU B 109 | 1.56A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE E 116CYH E 143SER E 139LEU E 164LEU E 109 | 1.59A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | CYH C 143SER C 139LEU C 153PHE C 116LEU C 109 | 1.41A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE C 116CYH C 143SER C 139LEU C 164LEU C 109 | 1.57A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE D 116CYH D 143SER D 139LEU D 164LEU D 109 | 1.54A | NoneNoneNoneNoneEDO D 204 ( 4.5A) | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE D 116CYH D 143SER D 139LEU D 164LEU D 109 | 1.61A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE A 116CYH A 143SER A 139LEU A 164LEU A 109 | 1.63A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE B 116CYH B 143SER B 139LEU B 164LEU B 109 | 1.61A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | CYH B 143SER B 139LEU B 153PHE B 116LEU B 109 | 1.44A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | PHE C 116CYH C 143SER C 139LEU C 164LEU C 109 | 1.58A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 694CYH A 697LEU A 469MET A 633LEU A 786 | 1.66A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | SER A 635LEU A 663MET A 626LEU A 469LEU A 636 | 1.74A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 694CYH A 697LEU A 469MET A 633LEU A 786 | 1.73A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 694CYH A 697LEU A 469MET A 633LEU A 786 | 1.71A | None | |||
![]() | 5Y2O_A_8N6A501_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bv2 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | PHE A 843SER C 10PHE A 415LEU A 437LEU C 40 | 1.63A | None |